**Core Concept**
Acute Myeloid Leukemia (AML) is a heterogeneous group of malignancies characterized by the clonal expansion of myeloid blasts in the bone marrow. The prognosis of AML varies widely depending on several factors, including the specific genetic abnormalities present in the leukemia cells.

**Why the Correct Answer is Right**
The best prognosis in AML is seen with **t(8;21) translocation**, also known as AML1-ETO fusion. This translocation involves the fusion of the AML1 gene on chromosome 21 with the ETO gene on chromosome 8. The resulting AML1-ETO fusion protein disrupts normal hematopoiesis by inhibiting the function of the AML1 transcription factor. Patients with t(8;21) translocation typically have a higher complete remission rate and longer overall survival compared to those with other genetic abnormalities. The presence of the t(8;21) translocation is often associated with a more favorable clinical course and improved response to chemotherapy.

**Why Each Wrong Option is Incorrect**
**Option A:** **inv(16)** is a chromosomal abnormality that involves the CBFB gene and is associated with a more favorable prognosis, but not the best prognosis.
**Option B:** **t(15;17)** is a translocation that involves the PML gene and is associated with a more favorable prognosis, but not the best prognosis.
**Option C:** **Wild-type cytogenetics** refers to AML patients without any detectable chromosomal abnormalities. While some patients with wild-type cytogenetics may have a good prognosis, others may have a poor prognosis.

**Clinical Pearl / High-Yield Fact**
AML patients with t(8;21) translocation often have a more favorable clinical course and improved response to chemotherapy. This is because the AML1-ETO fusion protein disrupts normal hematopoiesis, leading to a more predictable and responsive leukemia.

**Correct Answer: C. Wild-type cytogenetics**